Search
                    Carboplatin Treatment Options in Missouri
A collection of 394 research studies where Carboplatin is the interventional treatment. These studies are located in the Missouri, United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
            337 - 348 of 394
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
                                
            
            
        Completed
                            
            
                Primary Objective:
* To assess the safety and the maximum tolerated dose(MTD) of iniparib as a single agent and in combination with chemotherapeutic regimens in patients with advanced solid tumors that are refractory to standard therapy.
Secondary Objectives:
* To assess the antitumor effect of iniparib (per Response Evaluation Criteria in Solid Tumors \[RECIST\]) Version 1.1 in patients with measurable disease.
* To characterize iniparib (and its metabolites, if possible) pharmacokinetics....  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/21/2014
            
            Locations: Investigational Site Number 840007, St Louis, Missouri         
        
        
            Conditions: Neoplasm Malignant
        
            
        
    
                
                                    A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
                                
            
            
        Terminated
                            
            
                P276-00 is a novel, potent, small-molecule, flavone-derived Cdk 4 D1, Cdk1 B, and Cdk9 T inhibitor, with potent cytotoxic effects against chemosensitive and chemoresistant cancer cell lines.This study is planned to compare efficacy of the standard chemotherapy regimen of gemcitabine and carboplatin when administered with or without P276-00 in subjects with advanced triple negative breast cancer.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                09/03/2014
            
            Locations: Washington University, St. Louis, Missouri         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Combination Chemotherapy in Treating Children With Neuroblastoma
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma.
PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.             
        
        
    Gender:
                ALL
            Ages:
                20 years and below
            Trial Updated:
                07/31/2014
            
            Locations: University of Missouri - Columbia, Columbia, Missouri  +3 locations         
        
        
            Conditions: Neuroblastoma
        
            
        
    
                
                                    Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors.
PURPOSE: Phase III trial to compare the effectiveness of...  Read More             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                07/23/2014
            
            Locations: Children's Mercy Hospital, Kansas City, Missouri  +2 locations         
        
        
            Conditions: Kidney Cancer
        
            
        
    
                
                                    Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
PURPOSE: Phase I trial to study the effectiveness of colony-stimulating factors in treating children who have recurrent or refractory solid tumors and wh...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 21 years
            Trial Updated:
                07/23/2014
            
            Locations: Children's Mercy Hospital - Kansas City, Kansas City, Missouri         
        
        
            Conditions: Cancer
        
            
        
    
                
                                    Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
                                
            
            
        Terminated
                            
            
                This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet kno...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/29/2014
            
            Locations: CCOP - Kansas City, Kansas City, Missouri  +3 locations         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.             
        
        
    Gender:
                ALL
            Ages:
                2 years and below
            Trial Updated:
                03/27/2014
            
            Locations: Children's Mercy Hospital, Kansas City, Missouri         
        
        
            Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
        
            
        
    
                
                                    Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurren...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                02/12/2014
            
            Locations: Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri  +3 locations         
        
        
            Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
        
            
        
    
                
                                    Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vinblastine when given together with carboplatin in treating young patients with newly diagnosed or recurrent low-grade glioma.             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                02/11/2014
            
            Locations: Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St. Louis, Missouri         
        
        
            Conditions: Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
        
            
        
    
                
                                    Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
                                
            
            
        Completed
                            
            
                Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/10/2014
            
            Locations: Research Medical Center, Kansas City, Missouri         
        
        
            Conditions: Metastatic Melanoma
        
            
        
    
                
                                    Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells, allowing higher doses of chemotherapy to be used.
PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel when added to high-dose combination chemotherapy followed by peripheral stem cell transplantation in treating women with breast...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                01/09/2014
            
            Locations: St. Louis University Health Sciences Center, Saint Louis, Missouri         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells, allowing higher doses of chemotherapy to be used.
PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel added to a regimen of high-dose chemotherapy with cyclophosphamide and...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                01/09/2014
            
            Locations: St. Louis University Health Sciences Center, Saint Louis, Missouri         
        
        
            Conditions: Breast Cancer
        
            
        
    337 - 348 of 394
            